v3.26.1
Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Significant Accounting Policies [Abstract]  
Schedule of Depreciable Rates of Property and Equipment Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:

 

   %   Mainly
%
 
         
Laboratory equipment 10  10 
         
Computers, office furniture and equipment 6 - 33  33 
Schedule of Major Customer Data as a Percentage

Major customer data as a percentage of total revenues:

 

   Year ended December 31, 
   2025   2024   2023 
             
Cipher Pharmaceuticals (Canada)  11%  7%  11%
Chong Kun Dang Pharmaceuticals Corp. (South Korea)  19%  11%  25%
Gebro Holding GmbH (Austria)  19%  11%  18%
Ewopharma AG (Switzerland)  51%  30%  46%
Vetbiolix (France)  -%  41%  - 
                
Total  100%  100%  100%
Schedule of Antidilutive Shares

All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:

 

   Year ended December 31, 
   2025   2024   2023 
             
Options  49,533   41,610   27,492 
Warrants  2,604,096   886,599   617,337 
                
Total  2,653,629   928,209   644,829 

 

(*) Retroactively adjusted to give effect to the reverse share split, see also note 9.